PM360

APRIL 7, 2023

This is especially significant for manufacturers of high-cost specialty drugs, who will now face a recurring additional 20% charge on virtually every prescription fill. pharma sales in 2020) and the size of 340B discounts (25-50%), companies may see significantly reduced revenues for important products. The 340B battle will rage on.

Manufacturing 97

Manufacturing Insurance Marketing Government 97

Pharmaceutical Technology

JANUARY 16, 2023

Pharma may have to navigate a difficult path through relatively slow-to-fall inflation in regions outside the US. The legislation contains several provisions to lower prescription drug costs, including allowing Medicare to negotiate the cost of selected medicines. The entire pharma industry will be affected by the fallout.

Pharma 52

Pharma Pharmaceutical Manufacturing Marketing 52

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Technology

JANUARY 31, 2023

FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. That leaves three years for pharma companies to prepare. Nonetheless, Cailiff expressed optimism about US innovation and adaptability in the face of these changes.

FDA 52

FDA Prescription Medicine Biopharma 52

PM360

SEPTEMBER 21, 2023

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. Figure 1: Share of net spending for specialty and traditional prescription medications. The Uses—and Costs—of Specialty Treatments Keep Rising A U.S.

Prescription 52

Prescription Medical Patients Distribution 52

pharmaphorum

JANUARY 29, 2023

While global health spending per capita was about US$1,100 in 2018, this is forecast to rise to US$1,700 by 2026, outpacing GDP growth over the same period. In pharma, for instance, the global top 20 companies accounted for only about 35% market share in 1981, yet this figure had jumped to 65% by 2022.

Healthcare 98

Healthcare Healthcare Manufacturing Marketing 98

pharmaphorum

JUNE 29, 2022

The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth. COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026.

Doctors 59

Doctors Medicine Marketing Sales 59

Clarivate

AUGUST 20, 2024

Moreover, the initial set of negotiated prices represents the first step of a process that eventually will reshape the pricing and reimbursement landscape for prescription drugs under Medicare as CMS gradually replaces private payers as the chief negotiating partner for some of the drug industry’s largest-selling treatments.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Healthcare Success

JANUARY 27, 2025

Focus on Health Over Lifestyle Be direct and prioritize information about coverage for physicians, prescriptions, and chronic health conditions over lifestyle-focused advertising. We work with Pharma or Medicare or whatever. Be Transparent About Costs Include clear cost breakdowns (e.g., They're all different. It's changing.

Marketing 65

Marketing Education Media Leads 65

PM360

JANUARY 24, 2025

Patients on traditional Medicare have two entities paying their bills (Medicare for medical services and a Part D plan for prescription drugs), while those enrolled in Medicare Advantage (MA) plans have the same private entity paying for both medical and pharmacy services.

Food and Drug Administration 52

Food and Drug Administration Manufacturing Insurance Pharmaceutical 52

Clarivate

OCTOBER 17, 2024

Since the government first created a Part D benefit with the Medicare Modernization Act of 2003 (MMA) , Democrats have agitated for greater governmental input into the cost of prescription drugs for Medicare beneficiaries. Such a change would sharply increase the number of people covered under this program.

Healthcare 52

Healthcare Healthcare Government Insurance 52